Polymorphism rs5498 of the ICAM-1 gene affects the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus by Dražen Popović et al.
RESEARCH Open Access
Polymorphism rs5498 of the ICAM-1 gene
affects the progression of carotid
atherosclerosis in patients with type 2
diabetes mellitus
Dražen Popović1, Jovana Nikolajević Starčević2, Marija Šantl Letonja1, Jana Makuc3, Andreja Cokan Vujkovac3,
Ruda Zorc Pleskovič2, Ludovit Gaspar4*, Peter Kruzliak5* and Danijel Petrovič2*
Abstract
Background: Adhesion molecules are involved in the development of atherosclerosis. An increased level of the
ICAM 1 molecule is associated with numerous inflammatory diseases including atherosclerosis of carotid arteries.
The rs5498 (K469E) polymorphism of the ICAM-1 gene leads to an increase in the level of serum ICAM. We
investigated the association between the rs5498 (K469E) polymorphism of the ICAM-1 gene and the progression of
carotid atherosclerosis in subjects with type 2 diabetes mellitus (T2DM).
Methods: The study included 595 patients with T2DM and 200 subjects in the control group without T2DM. The
control examination was made 3.8 years after the initial examination. Indicators of atherosclerosis (carotid intima-
media thickness (CIMT), total plaque sum and sum of the plaques thickness) were detected by ultrasound
examination. Genetic analyses of the polymorphism rs5498 of the ICAM-1 gene were made by RT-PCR.
Results: The distribution of genotypes and frequencies of rs5498 polymorphism was not significantly different
between the group with type 2 diabetes ( T2DM) and the control group. Genotype EE K469E polymorphism is
associated with a statistically significant annual plaques growth.
Conclusion: The EE genotype of the rs5498 of the ICAM-1 gene was associated with a more rapid progression of
carotid atherosclerosis in patients with T2DM in comparison with other genotypes.
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Background
Atherosclerosis is a chronic inflammatory disease [1].
Type 2 diabetes mellitus (T2DM) is a chronic metabolic
disease. In patients with diabetes, cardiovascular compli-
cations are reported about 15 years earlier than in the
population without T2DM [2]. It has not been clarified
how T2DM affects the development of atherosclerosis.
It was reported that an increase of inflammatory cyto-
kine levels (IL-6, IL-18 and TNF- ɑ) might cause plaque
destabilization [3].
The leukocytes adhesion and their transendothelial
migration play an important role in the initial phase of
atherogenesis [4]. Processes are regulated by the various
types of adhesion molecules, such as the intercellular ad-
hesion molecule 1 (ICAM-1), the vascular cell adhesion
molecule 1 (VACAM 1) and the platelet endothelial cell
adhesion molecule 1 (PECAM 1). Their expression takes
place on the surface of endothelial cells, hematopoetic
cells, and immunological cells [5]. The plasma level of
adhesion molecules is elevated in individuals with ath-
erosclerosis [6–8]. The level of adhesion molecules in
the serum is also elevated in patients with T2DM [9].
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ICAM 1 is a transmembrane glycoprotein receptor con-
sisting of 505 amino acids, with molecular weight between
80 and 114 KDa depending on the degree of glycosylation
[10]. ICAM 1 belongs to the immunoglobulin superfamily.
It acts as a ligand β 2-integrin present on leukocytes. It
consists of five extracellular domains, a transmembrane
domain and a short cytoplasmic domain [11].
Increased concentrations of sl ICAM-1 were repored
in patients with cardiovascular disease, tumors, auto-
immune disease and other diseases with an inflamma-
tory reaction [7, 12, 13]. The gene for ICAM-1 is located
on the short arm chromosome 19. It consists of 15 775
base pairs, and it has seven exons and six introns com-
prising a relatively large non-translation region [14].
Translational start region is located in exon 1 [14].
The literature describes two polymorphisms of the
gene for ICAM 1, which affect the expression, K469E (rs
5498) and G241A (rs1799969) [15].
The rs5498 polymorphism in exon 6 of the gene for
ICAM-1 affects the structure of ICAM 1 and, conse-
quently, the migration of leukocytes in inflammatory mi-
lieu [16]. Motawi et al. found an increased incidence of
E alleles K469E polymorphism of ICAM 1 in patients
with peripheral and cardiovascular disease compared
with the control group [17].
Bjelinski et al. have found an association between the
K469E polymorphism and sl ICAM 1, however, there was
no correlation between calcium in coronary arteries and
circulating levels of sl ICAM 1 [18]. Milutinović and Pet-
rovič reported that the EE and KK genotype polymorph-
ism K469E for ICAM 1 was not associated with
myocardial infarction in patients with T2DM [19]. An in-
creased level of sl ICAM 1 in the healthy population
represents a risk for future heart attacks according to Rid-
ker et al. [13]. Those studies do not give a clear answer on
the relationship between the K469E polymorphism of
ICAM 1 and the development of cardiovascular diseases.
The purpose of the study was to investigate an associ-
ation between the rs5498 polymorphism of the ICAM-1




The study included 595 patients with T2DM and 200 sub-
jects without T2DM. Patients with T2DM were selected
from diabetic outpatient departments of the General Hos-
pital Murska Sobota and General Hospital Slovenj Gradec.
Control ultrasound examinations of the neck artery
were performed on 426 patients with T2DM and on 132
subjects in the control group. The period between the
first and the control ultrasound examination was 3.8 ±
0.5 years.
Patients with myocardial infarction (MI) and ischemic
stroke were not enrolled in the study. The study was ap-
proved by the National Medical Ethics Committee.
Ultrasound examination
High resolution B mode ultrasound analysis was per-
formed using the portable ultrasound system Toshiba
Aplio SSA-700 (Toshiba Medical. System Corp., Tokyo,
Japan) connected to a multi-frequency linear array trans-
ducer. All examinations were performed by a single ex-
pert radiologist. Patients were examined in the supine
position with the head tilted backwards. CIMT, defined
Table 1 Initially clinical and biochemical characteristics patients with T2DM and control subjects
Patients with T2DM n = 595 Subjects without T2DM n = 200 p
Age 61.38 ± 9.65 60.07 ± 9.18 0.07
Male sex (%) 338 (56.8) 92 (46.0) 0.008
Duration T2DM 11.25 ± 7.88 - -
Smoking (%) 53 (8.91) 34 (17.0) 0.002
Waist circumference (cm) 108.65 ± 12.88 93.31 ± 13.18 <0.001
BMI (kg/m2) 30.96 ± 4.74 27.90 ± 4.42 0.16
systolic pressure (mm Hg) 146.98 ± 19.98 143.3 ± 16.6 0.86
Diastolic pressure (mm Hg) 85.75 ± 11.62 84.7 ± 11.6 0.19
Fasting glucose (mmol/L) 8.04 ± 2.57 5.27 ± 0.87 <0.001
HbA1c (%) 7.89 ± 3.56 4.79 ± 0.29 <0.001
Total cholesterol (mmol/L) 4.70 ± 1.19 5.36 ± 1.08 <0.001
HDL cholesterol (mmol/L) 1.19 ± 0.35 1.43 ± 0.37 <0.001
LDL cholesterol (mmol/L) 2.63 ± 0,94 3.24 ± 0.98 <0.001
Triglycerides (mmol/L) 1.9 (1.2–2.7) 1.3 (0.9–1.9) <0.001
High sensitivity CRP (mg/L) 2.2 (1.0–4.3) 1.3 (0.8–2.7) <0.001
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as the distance from the leading edge of the lumen-
intima interface to the leading edge of the media-
adventitia interface, was measured at three sites along
the 10 mm long segment of the far wall of the common
carotid artery (CCA) free of plaques in agreement with
the carotid intima-media thickness consensus [20].
CIMT on the left and on the right were calculated as the
mean of three readings, and the mean of the left and
right CCA-CIMT measurements was used in the ana-
lysis. For the purpose of logistic regression analysis we
divided all the patients into two subgroups according to
the median CIMT value.
Biochemical analysis
Blood samples for biochemical analyses: fasting glucose,
glycated haemoglobin (HbA1c), total cholesterol, trigly-
ceride levels, high-density lipoprotein (HDL), low-
density lipoprotein (LDL) cholesterol level were col-
lected after a 12 h fasting period. All blood biochemical
analyses were determined by standard biochemical
methods in the hospital’s accredited lab.
Genotyping
Genomic DNA was extracted from 100 μL of whole
blood using a FlexiGene DNA isolation kit, in accord-
ance with the recommended protocol (Qiagene GmbH,
Hilden, Germany). The rs5498 polymorphism of the
ICAM-1 gene was determined with real-time PCR using
StepOne™ (48-well) Real-Time PCR Systems (Applied
Biosystems, Foster City, CA, USA). We used the comm-
mercially available genotyping kit TagMan SNP Geno-
typing assay (Applied Biosystem, Foster City, CA, USA)
following the manufacturer’s instructions. Moreover, we
used the following primers:-5’-CCATCGGGGAAT-
CAGTG-3’;- 5’-ACAGAGCACATTCACGGTC-3’).
Statistical analysis
Normality of distribution continuous variables was ex-
amined by using the Kolmogorov-Smirnov test. Continu-
ous variables which were normally distributed, showed
in the form of means ± standard deviations. Variables
that were not in normal distribution, were presented in
the form of median (interquartile range). To compare
the numerical values of the continuous variables, we
used Student’s t test or analysis of variance (ANOVA), if
the variables were normally distributed. Mann–Whitney
U test or Kruskal-Wallis H test if the variables were
asymmetrically distributed. To compare frequencies cat-
egorical variables, statistical evaluation of differences in
the frequencies of different alleles and genotypes be-
tween the two groups as well as in the case of determin-
ing the Hardy-Weinberg equilibrium, were used χ2 test.
The correlation between independent variables were
analyzed using the Pearson correlation analyzes. The re-
sults showed a high degree of correlation between the
serum levels of total and LDL cholesterol (r = 0.86; p
<0.001) as well as systolic and diastolic blood pressure
(r = 0.65, p <0.001). In the cases of a high degree correl-
ation between the two variables only one variable from
each pair were included in the multivariate statistical
models. Change in the value of ultrasound markers of
carotid artery atherosclerosis was calculated by deduct-
ing between value measured at two ultrasound
examination.
For searching association between polymorphisms of
selected candidate genes and their interactions with sta-
tins treatment and indicators of progression carotid ar-
tery atherosclerosis were used multivariate linear
regression analysis. The criteria for a statistically signifi-
cant difference is p value less then 0.05. To reduce the
possibility of error due to the small number of subjects
were used Bonferronis correction. All statistical analyzes
Table 2 Changes in echo markers of carotid atherosclerosis in patients with T2DM and control subjects between the first and
control echo examination after 3.8 ± 0.5 years
Patients with T2DM n = 426 Subjects without T2DM n = 137 p
Annual CIMT increment (μm/year) 20.33 (11.74–29.86) 12.83 (8.82–20.66) 0.02
Δ number of plaque segments 2.0 (1.0–3.0) 1.5 (0.7–2.2) 0.03
Δ sum of the plaques thickness (mm) 5.40 (2.40–7.05) 3.64 (2.88–5.48) 0.02
Δ- variable value changes during the observation period, expressed as a percentage of baseline values
Table 3 Distribution of rs5498 genotypes for ICAM-1 in patients with T2DM and control subjects without T2DM
Patients with T2DM n = 595 Subjects without T2DM n = 200 p
KK genotype 172 (28.9) 59 (29.5) 0.87
EK genotype 306 (51.4) 105 (52.5)
EE genotype 117 (19.7) 36 (18.0)
K allele 650 (54.6) 223 (55.8) 0.69
E allele 540 (45.4) 177 (44.2)
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were performed using a computer program SPSS for
Windows, version 20 (Statistical Package for the Social
Sciences Inc., Chicago, IL, USA).
Results
Basic clinical characteristics and biochemical laboratory
results are shown in Table 1. There were no statistically
significant differences in age, body mass index, systolic
and diastolic blood pressure between the group with
T2DM and the control group. Waist circumference was
significantly higher in the T2DM group, as well as the
number of smokers (Table 1). A biochemical examin-
ation in patients with T2DM showed statistically signifi-
cant higher levels of fasting glucose, HbA1c, total
cholesterol, HDL, LDL, triglyceride and CRP-a com-
pared with the control group (Table 1).
A control ultrasound examination of the carotid artery
was made 3.8 ± 0.5 years after the initial examination.
The progression of atherosclerotic markers (change in
annual CIMT, change in the number of plaque seg-
ments, and change in the sum of the plaque thickness)
was more intense in subjects with T2DM in comparison
with subjects without T2DM (Table 2).
The distribution of rs5498 genotypes in patients with
T2DM and the control group are presented in Table 3.
There are no statistically significant differences in the
distribution of genotypes in patients with T2DM and the
control group. The distribution of genotypes in the
population of patients with T2DM was in Hardy-
Weinberg equilibrium (SB2: χ2 = 0.83; p = 0.36; healthy
controls: χ2 = 0.82; p = 0.36).
Ultrasound markers of carotid artery atherosclerosis
in patients with T2DM were compared between the
first and the second examination in comparison to
the rs5498 genotypes. There was a statistically signifi-
cant difference in the annual increment of CIMT with
regard to rs5498-ICAM genotypes, i.e. subjects with
T2DM with the EE genotype had the biggest enlarg-
ment of CIMT per year in comparison with other ge-
notypes (Table 4). We did not demonstrate, however,
a statistically significant differences in subclinical
markers of carotid atherosclerosis with regard to
rs5498-ICAM genotypes in subjects without T2DM
(Table 4).
Table 5 demonstrates the effect of rs5498 genotypes
on progression of markers of carotid atherosclerosis in
patients with T2DM due to statin treatment. We dem-
onstrated the EE genotype of the rs5498 to be associated
with higher statistically significant annual increment of
CIMT in subjects with T2DM that were not on statin
treatment.
Table 6 shows the relation in incidence of unstable
plaques in patients with T2DM, adjusted to the classical
risk factors for atherosclerosis and genotypes K469E
polymorphism for ICAM 1 upon the inclusion in the
study. When adjusted to other risk facotors, the rs5498
EE genotype had an independent effect on the presence
of unstable plaques on the carotid artery.
Table 4 Changes in ultrasound markers of carotid artery atherosclerosis in subjects with T2DM and without T2DM between the first
and second ultrasound examination of the carotid arteries according to rs5498 ICAM genotypes
KK genotype KE genotype EE genotype p
Subjects with T2DM
Annual CIMT increment (μm/year) 12.76 (5.26–23.96) 20.34 (12.50–28.04) 26.09 (20.69–32.42) 0.04
Δ number of plaque segments 1.0 (0.5–3.0) 2.0 (1.0–2.5) 3.0 (2.0–3.0) 0.65
Δ sum of the plaques thickness (mm) 4.3 (1.4–7.8) 5.4 (1.55–10.15) 6.3 (2.3–8.1) 0.62
Subjects without T2DM
Annual CIMT increment (μm/year) 10.22 (6.72–17.85) 13.47 (10.24–19.66) 16.46 (10.32–21.82) 0.12
Δ number of plaque segments 1.0 (0.5–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.42
Δ sum of the plaques thickness (mm) 2.8 (1.3–6.2) 3.8 (1.40–6.08) 4.5 (1.8–6.64 0.58
Δ- variable value changes during the observation period, expressed as a percentage of baseline values
Table 5 Association of ICAM-1 polymorphism with carotid atherosclerosis progression in patients with T2DM due to statin
treatment
Statin treatment KK genotype KE genotype EE genotype p
Annual CIMT increment (μm/year) + 11.77 (6.24–16.19) 18.06 (14.45–23.08) 22.62 (17.81–29.48) 0.13
- 14.27 (10.22–19.32) 21.28 (15.21–28.27) 28.04 (24.32–32.56) 0.04
Δ sum of the plaques thickness (mm) + 3.76 (2.8–5.40) 4.69 (3.68–5.12) 5.86 (4.16–7.68) 0.30
- 4.92 (3.76–6.48) 6.40 (4.66–8.02) 6.93 (4.76–8.31) 0.74
Δ number of plaque segments + 1.0 (0.5–2.0) 1.5 (1.0–3.0) 2.0 (1.0–3.0) 0.23
- 1.0 (0.5–2.0) 2.0 (1.0–3.0) 3.0 (0.5–3.0) 0.57
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Table 7 shows the results of multiple linear regression,
adjusted to classic risk factors for atherosclerosis and
rs5498-ICAM genotypes. When adjusted to other risk
factors, the rs5498 EE genotype had an independent ef-
fect on the annual enlargement of CIMT in subjects
with T2DM.
Discussion
An association between the rs5498 polymorphism of the
ICAM-1 gene and the progression of carotid atheroscler-
osis in subjects with T2DM was demonstrated in the
present study. We found an association between the EE
genotype of rs5498-ICAM-1 and the annual increment
of CIMT. Moeover, a regression analysis demonstrated
an association between the EE genotype of rs5498-
ICAM-1 and the presence of unstable plaques in the ca-
rotid arteries. Our study is the first to establish an asso-
ciation between the rs5498-ICAM-1and the progression
of carotid atherosclerosis. ICAM-1, produced by endo-
thelial cells during inflammatory reactions, is involved in
the adhesion reaction of monocytes, macrophages, T
lymphocytes, and platelets to each other and to the ves-
sel wall, which all favour the atherosclerotic process
[21]. Moreover, ICAM-1 is involved in the interaction
through intergrin receptors on leukocytes which enabled
the binding to endothelial cells and transendotelial mi-
gration of leukocytes in the intima and leukocytes accu-
mulations in vascular wall [14].
Several studies support the hypothesis that the
ICAM 1 might influence the development of athero-
sclerosis. Pola and co-workers demonstrated that the
EE genotype of the rs5498 was twice as frequent in
patients with CVI than in the control group, indicat-
ing the the rs5498 was a genetic risk for ischemic
stroke [22]. The association between the rs5498 poly-
morphism and coronary heart disease was not
demonstrated in Caucasians in Ireland and Slovenia
[19, 23]. In epidemiological studies in a seemingly
healthy population, elevated levels of sl ICAM-1 were
reported to be associated with an increased risk for
the development of cardiovascular disease, periferal
vascular disease, carotid artery disease and cerebro-
vascular stroke [7, 13, 24, 25]. Tang and co-workers
reported that the level of serum ICAM-1 was associ-
ated with calcium score as a marker of coronary ath-
erosclerosis. Moreover, they concluded that sICAM-1
might be a biomarker for coronary atherosclerosis
[26]. Gaetan et al. in the Italian population and
Shaker et al. in the Egyptian population reported that
the EE genotype of the rs5498 was significantly more
Table 6 Adjusted analysis of rs5498-ICAM gene polymorphism and the presence of plaques/unstable plaques in the carotid arteries
in patients with T2DM upon the inclusion in the study
Presence of the plaques Presence of the unstable plaques
OR (95 % CI) p OR (95 % CI) p
Hypertension (0 = no; 1 = yes) 2.43 0.25 1.56 0.38
Systolic pressure (mmHg) 0.12 0.44 0.17 0.37
Serum LDL (mmol/L) 1.45 0.32 1.22 0.71
Serum HDL (mmol/L) 0.15 0.03 0.48 0.76
Hba1c (%) 0.72 0.10 1.14 0.49
KE 0.97 0.49 0.74 0.17
EE 0.85 0.51 1.69 0.03
All models were adjusted by age, sex, smoking, and treatment with statins. The reference group are homozygotes for allele K
Table 7 Relation between genotypes K469E polymorphism for ICAM 1 gene and the progress of carotid artery atherosclerosis in
patients with T2DM
ΔCIMT/year Δ Plaques segments Δ Sum of the plaques thickness
β p β p β p
Hypertension (0 = no; 1 = yes) 1.45 0.35 1.26 0.64 1.46 0.92
Systolic pressure (mmHg) 0.12 0.44 0.08 0.32 0.45 0.48
Serum LDL (mmol/L) 0.32 0.40 0.07 0.69 0.53 0.41
Serum HDL (mmol/L) −0.04 0.18 −0.51 0.34 −0.39 0.90
Hba1c (%) 0.89 0.70 0.13 0.43 0.68 0.28
KE 1.37 0.49 0.74 0.17 1.14 0.37
EE 3.69 0.03 0.25 0.51 1.31 0.62
All models were adjusted by age, sex, smoking, and treatment with statins
The reference group are homozygotes for allele K
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frequent in patients with peripheral arterial oclusive
disease than in the control group [27, 28].
Finally, in the study we demonstrated the EE genotype
of the rs5498 to be associated with higher statistically
significant annual increment of CIMT in subjects with
T2DM that were not on statin treatment.
The rs5498-ICAM-1 polymorphism was reported to
be associated with an increased expression of ICAM-1
in our study in which subjects with T2DM with diabetic
retinopathy were enrolled [29]. Namely, significantly
higher sICAM-1 serum levels were demonstrated in
Caucasian subjects with T2DM with the EE genotype
compared with those with other (EK + KK) genotypes
(918 ± 104 vs. 664 ± 209 microg/L; P = 0.001) [29]. We
presume that the inceased expression of ICAM-1 might
lead to an increased leukocytes adhesion to the vessel
wall endothelium and the atherosclerotic process [30].
In their study, De Graba et al. found an increased ex-
pression of ICAM-1 in symptomatic in comparison to
asymptomatic plaques [31]. Contrary to this report,
however, Nuotio and co-workers did not report about an
increased expression of ICAM 1, VACAM 1, E-selectin
and P-selectin in symptomatic carotid plaques [32]. The
rs5498 of the ICAM-1 gene results in a change in the
amino acid sequence of the immunoglobulin-like do-
main 5. This domain is of crucial importance for the ac-
tivity of the ICAM-1 protein [33]. We speculate that the
EE genotype might affect the development of athero-
sclerotic markers via increased sICAM-1 serum activity.
Conclusion
In our study, the EE genotype of the rs5498 of the
ICAM-1 gene was associated with a more rapid progres-
sion of carotid atherosclerosis in subjects with T2DM in
comparison with other genotypes.
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